<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DACARBAZINE- dacarbazine injection, powder, for solution </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Dacarbazine for Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="a77f23ba-a7d5-4a49-b201-d2a734e2e281"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First">It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.</p>
<p> </p>
<p>1. Hemopoietic <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is the most common toxicity with dacarbazine (see <span class="Bold"><span class="Emphasis"><a href="#b0afe3a5-b3c9-450d-a7c7-3e5ef1161096">WARNINGS</a></span></span>).</p>
<p>2. <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">Hepatic necrosis</span> has been reported (see <span class="Bold"><span class="Emphasis"><a href="#b0afe3a5-b3c9-450d-a7c7-3e5ef1161096">WARNINGS</a></span></span>).</p>
<p>3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.</p>
<p>4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.</p>
<br><br><br>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="cb3d6e1b-8b3f-4d97-865d-b1628d6a8c71"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dacarbazine for Injection, USP is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow colored solid which is light sensitive.  Each vial contains 100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol.  Dacarbazine for Injection, USP is reconstituted and administered intravenously (pH 3-4).  Dacarbazine for Injection, USP is an anticancer agent.  Chemically, dacarbazine is 5-(3,3-Dimethyl-1-triazeno) imidazole-4-carboxamide with the following structural formula:</p>
<p> <img alt="dacarbazine-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216&amp;name=dacarbazine-for-injection-usp-figure-1-dacarbazine-structure.jpg"></p>
<p> </p>
<p>M.W. 182.19                                            C<span class="Sub">6</span>H<span class="Sub">10</span>N<span class="Sub">6</span>O</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f8f91061-33c5-4d8e-9c73-1f6d20fbe017"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">After intravenous administration of dacarbazine for injection, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver.  Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours.<span class="Sup">1</span>  In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours.<span class="Sup">1</span>  The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours.<span class="Sup">1</span>  Dacarbazine is subject to renal tubular secretion rather than glomerular filtration.  At therapeutic concentrations dacarbazine is not appreciably bound to human plasma protein.</p>
<p>In man, dacarbazine for injection is extensively degraded.  Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine.  AIC is not derived endogenously but from the injected dacarbazine, because the administration of radioactive dacarbazine labeled with <span class="Sup">14</span>C in the imidazole portion of the molecule (dacarbazine-2-<span class="Sup">14</span>C) gives rise to AIC-2-<span class="Sup">14</span>C.<span class="Sup">1 </span></p>
<p>Although the exact mechanism of action of dacarbazine is not known, three hypotheses have been offered:</p>
<p>1. inhibition of DNA synthesis by acting as a purine analog</p>
<p>2. action as an alkylating agent</p>
<p>3. interaction with SH groups</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d8de8e52-0335-4e86-b7c3-5096927f53f0"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma.  In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="dc84f340-1afb-4fc2-be1c-f2ab73c256ac"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Dacarbazine for Injection is contraindicated in patients who have demonstrated a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it in the past.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b0afe3a5-b3c9-450d-a7c7-3e5ef1161096"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Hemopoietic <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is the most common toxicity with dacarbazine for injection and involves primarily the leukocytes and platelets, although, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> may sometimes occur.  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may be severe enough to cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  The possible <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> requires careful monitoring of white blood cells, red blood cells, and platelet levels.  Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with dacarbazine for injection.</p>
<p>Hepatic toxicity accompanied by <span class="product-label-link" type="condition" conceptid="4301208" conceptname="Hepatic vein thrombosis">hepatic vein thrombosis</span> and hepatocellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported.  The incidence of such reactions has been low; approximately 0.01% of patients treated.  This toxicity has been observed mostly when dacarbazine for injection has been administered concomitantly with other antineoplastic drugs; however, it has also been reported in some patients treated with dacarbazine for injection alone.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> can occur following the administration of dacarbazine for injection.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e1f59d63-ab5e-4998-8526-cd9e670070c2"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Hospitalization is not always necessary but adequate laboratory study capability must be available.  <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of the drug subcutaneously during intravenous administration may result in tissue damage and severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  Local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, and irritation at the site of injection may be relieved by locally applied hot packs.</p>
<p>Carcinogenicity of dacarbazine was studied in rats and mice.  Proliferative endocardial lesions, including <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> were induced by dacarbazine in rats.  In mice, administration of dacarbazine resulted in the induction of angiosarcomas of the spleen.</p>
<div class="Section" data-sectionCode="42232-9">
<a name="fc7f1bc4-4195-451c-b6aa-380d45502677"></a><a name="section-6.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Teratogenic Effects, Pregnancy Category C.</span></span></p>
<p>Dacarbazine has been shown to be teratogenic in rats when given in doses 20 times the human daily dose on day 12 of gestation.  Dacarbazine when administered in 10 times the human daily dose to male rats (twice weekly for 9 weeks) did not affect the male libido, although female rats mated to male rats had higher incidence of resorptions than controls.  In rabbits, dacarbazine daily dose 7 times the human daily dose given on Days 6-15 of gestation resulted in fetal skeletal anomalies.  There are no adequate and well controlled studies in pregnant women.  Dacarbazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for dacarbazine in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="bf116fe0-69ef-420d-b0cf-5832ab28c061"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are the most frequently noted of all toxic reactions.  Over 90% of patients are affected with the initial few doses.  The <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> lasts 1-12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine.  Rarely, intractable <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have necessitated discontinuance of therapy with dacarbazine for injection.  Rarely, dacarbazine has caused <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  Some helpful suggestions include restricting the patient’s oral intake of food for 4-6 hours prior to treatment.  The rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days.</p>
<p>There are a number of minor toxicities that are infrequently noted.  Patients have experienced an <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like syndrome of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> to 39°C, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.  These symptoms occur usually after large single doses, may last for several days, and they may occur with successive treatments.</p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> has been noted as has <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">facial paresthesia</span>.  There have been few reports of significant liver or renal function test abnormalities in man.  However, these abnormalities have been observed more frequently in animal studies.</p>
<p>Erythematous and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticarial rashes</span> have been observed infrequently after administration of dacarbazine for injection.  Rarely, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ae9ae0cc-22d8-4bbe-9190-3fafb206c31e"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Give supportive treatment and monitor blood cell counts.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="cd75e856-08dc-49c2-8e8c-d6c0b931182e"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="bb2f34e5-d2e2-4e0f-ac24-1773587371da"></a><a name="section-9.1"></a><p></p>
<h2>Malignant Melanoma<br>
</h2>
<p class="First">The recommended dosage is 2 to 4.5 mg/kg/day for 10 days.  Treatment may be repeated at 4 week intervals.<span class="Sup">2 </span></p>
<p>An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days.  Treatment may be repeated every 3 weeks.<span class="Sup">3,4</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bc8e4b0f-f38d-4cfb-855e-197622032d29"></a><a name="section-9.2"></a><p></p>
<h2>Hodgkin's Disease<br>
</h2>
<p class="First">The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs.  Treatment may be repeated every 4 weeks.<span class="Sup">5</span>  An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.<span class="Sup">6 </span></p>
<p>Dacarbazine for Injection, USP 100 mg/vial and 200 mg/vial are reconstituted with 9.9 mL and 19.7 mL, respectively, of Sterile Water for Injection, USP.  The resulting solution contains 10 mg/mL of dacarbazine having a pH of 3.0 to 4.0.  The calculated dose of the resulting solution is drawn into a syringe and administered <span class="Italics"><span class="Emphasis">only</span></span> intravenously.</p>
<p>The reconstituted solution may be further diluted with 5% Dextrose Injection or Sodium Chloride Injection and administered as an intravenous infusion.</p>
<p>After reconstitution and prior to use, the solution in the vial may be stored at 4°C for up to 72 hours or at normal room conditions (temperature and light) for up to 8 hours.  If the reconstituted solution is further diluted in 5% Dextrose Injection or Sodium Chloride Injection, the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.</p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered.  Several guidelines on this subject have been published.<span class="Sup">7-13</span>  There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="dc5c775f-c894-401b-a31b-8c2135e61a9e"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br><table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">102710</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-127-10</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Dacarbazine 100 mg/vial in 10 mL vials, in packages of 10.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">102820</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-128-20</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Dacarbazine 200 mg/vial in 20 mL vials, in packages of 10.</p></td>
</tr>
</tbody></table>
<br><p class="First"><span class="Bold"><span class="Emphasis">STORE IN A REFRIGERATOR 2°-8°C (36°-46°F).</span></span></p>
<p><span class="Bold"><span class="Emphasis">PROTECT FROM LIGHT.</span></span></p>
<p><span class="Bold"><span class="Emphasis">USE WITHIN 8 HOURS OF RECONSTITUTION.</span></span></p>
<p>Vial stoppers do not contain natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="f795447f-7612-4bb5-9955-33c8d633c519"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Loo, T.J., <span class="Italics"><span class="Emphasis">et al.:</span></span> Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treatment Reports 60: 149-152, 1976.</li>
<li>Nathanson, L., <span class="Italics"><span class="Emphasis">et al.:</span></span> Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma. Clinical Pharmacology and Therapeutics 12: 955-962, 1971.</li>
<li>Costanza, M.E., <span class="Italics"><span class="Emphasis">et al.:</span></span> Therapy of malignant melanoma with an imidazole carboxamide and bischloroethyl nitrosourea. Cancer 30: 1457-1461, 1972.</li>
<li>Luce, J.K., <span class="Italics"><span class="Emphasis">et al.:</span></span> Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388). Cancer Chemotherapy Reports 54: 119-124, 1970.</li>
<li>Bonadonna, G., <span class="Italics"><span class="Emphasis">et al.:</span></span> Combined Chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.  Cancer Treatment Reports 61: 769-777, 1977.</li>
<li>Santoro, A., and Bonadonna, G.: Prolonged disease-free survival in MOPP- resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).  Cancer Chemotherapy Pharmacol, 2: 101-105, 1979.</li>
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.</li>
<li>AMA Council Report, Guidelines for Handling Parenteral Antineoplastics. JAMA, 1985; 253 (11): 1590-1592.</li>
<li>National Study Commission on Cytotoxic Exposure Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.</li>
<li>Clinical Oncological Society of Australia, Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia, 1983; 1: 426-428.</li>
<li>Jones RB, <span class="Italics"><span class="Emphasis">et al:</span></span> Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA - A Cancer Journal for Clinicians, 1983; (Sept/Oct) 258-263.</li>
<li>American Society of Hospital Pharmacists Technical Assistance Bulletin on  Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm, 1990; 47:1033-1049.</li>
<li>OSHA Work-Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. Am J Hosp Pharm, 1986; 43: 1193-1204.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bb3aa37b-c6dd-4f89-988e-3f0c4a5a5402"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216&amp;name=dacarbazine-for-injection-usp-figure-2-add_band_logo.jpg"> </p>
<p>45650C</p>
<p>Revised: January 2008 </p>
<p> </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bc2dc85d-ebcf-4e3b-9a4b-d5130e837e81"></a><a name="section-13"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Dacarbazine 100 mg Vial Label</span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-127-10 </p>
<p>102710</p>
<p><span class="Bold"><span class="Emphasis">Dacarbazine for Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">100 mg </span></span></p>
<p>prepared as the citrate salt</p>
<p>For IV Use Only</p>
<p>Single Dose Vial</p>
<p>Rx only</p>
<p>Discard Unused Portion</p>
<p><img alt="102710-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216&amp;name=dacarbazine-for-injection-usp-figure-3-102710-vial.jpg"> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Dacarbazine 200 mg Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-128-20 </p>
<p>102820</p>
<p><span class="Bold"><span class="Emphasis">Dacarbazine for Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">200 mg </span></span></p>
<p>prepared as the citrate salt</p>
<p>For IV Use Only</p>
<p>Single Dose Vial</p>
<p>Rx only</p>
<p>Discard Unused Portion</p>
<p><img alt="102820-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216&amp;name=dacarbazine-for-injection-usp-figure-4-102820-vial.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DACARBAZINE 		
					</strong><br><span class="contentTableReg">dacarbazine injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-127</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DACARBAZINE</strong> (DACARBAZINE) </td>
<td class="formItem">DACARBAZINE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-127-10</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075371</td>
<td class="formItem">09/07/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DACARBAZINE 		
					</strong><br><span class="contentTableReg">dacarbazine injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-128</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DACARBAZINE</strong> (DACARBAZINE) </td>
<td class="formItem">DACARBAZINE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">3.75 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-128-20</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075371</td>
<td class="formItem">09/07/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE(63323-127, 63323-128)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cee49be4-a9e3-4f9f-852e-a3d3b25ac44f</div>
<div>Set id: b6b97e41-5f15-498c-abfb-d8443ea4d216</div>
<div>Version: 1</div>
<div>Effective Time: 20120904</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
